Modality
ADC
MOA
Menini
Target
TROP-2
Pathway
Sphingolipid
PBC
Development Pipeline
Preclinical
Feb 2023
→ Oct 2028
PreclinicalCurrent
NCT03493720
1,986 pts·PBC
2023-02→2028-10·Active
1,986 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-10-042.5y awayInterim· PBC
Trial Timeline
2023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
Preclinical
Active
Catalysts
Interim
2028-10-04 · 2.5y away
PBC
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03493720 | Preclinical | PBC | Active | 1986 | NT-proBNP |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Mavutenlimab | Johnson & Johnson | Phase 3 | Cl18.2 | |
| Ivorelsin | Eli Lilly | Approved | JAK1 | |
| NVS-4076 | Novartis | Preclinical | TROP-2 | |
| NVS-8902 | Novartis | Preclinical | TROP-2 | |
| NVO-2974 | Novo Nordisk | NDA/BLA | PARP | |
| Zanumavacamten | GSK | Phase 2/3 | TROP-2 | |
| ION-1378 | Ionis | NDA/BLA | TROP-2 | |
| Nirafotisoran | Jazz Pharma | Phase 2/3 | TROP-2 | |
| ILM-4317 | Illumina | NDA/BLA | TROP-2 | |
| Olpafutibatinib | Immunocore | Approved | SMN2 |